Study protocol: the biologics in severe chronic rhinosinusitis with nasal polyps survey
Favier,V.,Daveau,C.,Carsuzaa,F.,Fieux,M.,Vandersteen,C.,Castillo,L.,Papon,J. F.,de Gabory,L.,Saroul,N.,Verillaud,B.,Rumeau,C.,Jankowski,R.,Michel,J.,de Bonnecaze,G.,Lecanu,J.-B.,Coste,A.,Bequignon,E.,Malard,O.,Mortuaire,G.
DOI: https://doi.org/10.1136/bmjopen-2023-083112
IF: 3.006
2024-05-16
BMJ Open
Abstract:Introduction Chronic rhinosinusitis with nasal polyps (CRSwNP) is a frequent condition affecting approximately 2% of the population. Medical treatment consists long-term use of intranasal corticosteroids and short-term use of oral corticosteroids, in adjunct with saline solution rinses. Surgical management is proposed in patients who failed after medical treatment. In France, two biologics are reimbursed in case of severe uncontrolled CRSwNP despite medical treatment and endoscopic sinus surgery. Waiting for head-to-head biologics comparison, studies should report the efficacy and safety of biologics in large real-life cohorts. This study protocol describes the aims and methods of a prospective, observational, national, multicentric cohort of patients with CRSwNP treated with biologics. Methods and analysis The BIOlogics in severe nasal POlyposis SurvEy is a French multicentre prospective observational cohort study. The main aim is to assess the efficacy and tolerance of biologics in patients with CRSwNP, with or without association with other type 2 diseases, and to determine the strategies in case of uncontrolled disease under biologics. Patients over 18 years old requiring biologics for CRSwNP in accordance with its marketing approval in France (ie, severe nasal polyposis, with lack of control under nasal corticosteroid, systemic corticosteroids and surgery) are invited to participate. Collected data include topical history of surgical procedures and biologics, medication and use of systemic corticosteroids, visual analogical scales for specific symptoms, Sino-Nasal Outcome Test-22 questionnaire, nasal polyp score, asthma control test, Lund-Mackay score on CT scan and IgE concentration and eosinophilic count on blood sample. Trial registration NCT05228041/DRI_2021/0030.
medicine, general & internal